Colombia: The Top Choice for Medtech Early-Feasibility and First-in-Human Trials

Written By Julio G. Martinez-Clark

Discover why Colombia is ideal for Medtech early-feasibility studies (EFS) and first-in-human (FIH) clinical trials. As the third-largest country in Latin America and an Organization for Economic Cooperation and Development (OECD) member, Colombia offers strategic advantages with its free trade agreements with the US and the EU and its prime geographical location in the same Eastern Standard Time (EST) zone. These factors have made Colombia the top destination in Latin America for first-in-human Medtech clinical trials.

After a fast institutional review board (IRBs are also called ethics committees or ECs) approval, the Ministry of Health in Colombia ensures a predictable study review process, typically taking between 90 and 120 days. Additionally, sponsors can expect significant cost savings, with hospital fees reduced by about 30-50%.

Explore our infographic to see why prominent Medtech sponsors like DirectFlow, InterVene, Mitralign, MitraSpan, Kona Medical, Avinger, CeloNova, Libella, enVVeno, ReGelTec, Sonnest, PAVmed, Watershed, Spine Stabilization Technologies, and many others choose Colombia for their clinical research needs. Discover the unparalleled benefits that make Colombia the prime destination for your Medtech clinical trial.

Colombia: The Top Choice for Medtech Early-Feasibility and First-in-Human Trials
El Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) es la entidad autorizada por el Ministerio de Salud y Protección Social para evaluar y aprobar proyectos de investigación clínica con medicamentos y dispositivos médicos en seres humanos en Colombia. La Sala Especializada de Dispositivos Médicos y Reactivos de Diagnóstico In Vitro del INVIMA evalúa solicitudes de aprobación de estudios de investigación clínica aproximadamente cada 30 días; esto hace que el país sea uno de los más competitivos de Latinoamérica para este tipo de estudios. Sin embargo, llegó el momento de crear una ley de investigación en clínica en humanos clara, moderna y competitiva que garantice que Colombia se convierta en uno de los países más innovadores en salud de América Latina para el 2025. Julio G. Martinez-Clark http://www.juliomartinezclark.com/
Previous

Travel Guide: Essential Tips for Visiting Colombia for Medical Device Clinical Trials
Next

Frequently Asked Questions About Medical Device Clinical Trials in Colombia